[go: up one dir, main page]

MX2018011679A - Biomarcadores de proteopatias y usos de los mismos. - Google Patents

Biomarcadores de proteopatias y usos de los mismos.

Info

Publication number
MX2018011679A
MX2018011679A MX2018011679A MX2018011679A MX2018011679A MX 2018011679 A MX2018011679 A MX 2018011679A MX 2018011679 A MX2018011679 A MX 2018011679A MX 2018011679 A MX2018011679 A MX 2018011679A MX 2018011679 A MX2018011679 A MX 2018011679A
Authority
MX
Mexico
Prior art keywords
subject
proteopathy
determining
proteopathies
biomarkers
Prior art date
Application number
MX2018011679A
Other languages
English (en)
Inventor
Pablo Sardi Sergio
Scherzer Clemens
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2018011679A publication Critical patent/MX2018011679A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)

Abstract

En la presente se proporcionan métodos para determinar la eficacia de un tratamiento para una proteopatía, diagnosticar una proteopatía en un sujeto, determinar si un sujeto está en riesgo de desarrollar una proteopatía, determinar la etapa de una proteopatía en un sujeto, monitorear una proteopatía en un sujeto, seleccionar un tratamiento para una proteopatía para un sujeto y seleccionar un sujeto para un ensayo clínico que incluye determinar un nivel de al menos un esfingolipido en una muestra que incluye un fluido biológico del sujeto.
MX2018011679A 2016-03-25 2017-03-24 Biomarcadores de proteopatias y usos de los mismos. MX2018011679A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313638P 2016-03-25 2016-03-25
US201662372523P 2016-08-09 2016-08-09
PCT/US2017/024012 WO2017165766A2 (en) 2016-03-25 2017-03-24 Biomarkers of proteopathies and uses thereof

Publications (1)

Publication Number Publication Date
MX2018011679A true MX2018011679A (es) 2019-06-24

Family

ID=58547821

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011679A MX2018011679A (es) 2016-03-25 2017-03-24 Biomarcadores de proteopatias y usos de los mismos.

Country Status (10)

Country Link
US (1) US20200124624A1 (es)
EP (1) EP3433623A2 (es)
JP (2) JP6940515B2 (es)
KR (1) KR20180124971A (es)
AU (1) AU2017238769A1 (es)
CA (1) CA3018745A1 (es)
IL (1) IL261906A (es)
MA (1) MA44484A (es)
MX (1) MX2018011679A (es)
WO (1) WO2017165766A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201803553D0 (en) * 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
JP7600124B2 (ja) 2019-02-04 2024-12-16 フリーライン セラピューティクス リミテッド ポリヌクレオチド
US20230201136A1 (en) * 2020-02-28 2023-06-29 Genemo, Inc. Methods and materials for diagnosis and treatment of neuronal disorder
CA3198606A1 (en) * 2020-10-14 2022-04-21 Denali Therapeutics Inc. Methods for treating and monitoring frontotemporal dementia
CN112798727B (zh) * 2021-04-09 2021-07-06 宝枫生物科技（北京）有限公司 用于诊断脑白质病变的生物标志物f7及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8781557B2 (en) 1999-08-11 2014-07-15 Osteoplastics, Llc Producing a three dimensional model of an implant
WO2001097829A2 (en) * 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
JP4884367B2 (ja) * 2004-02-24 2012-02-29 アボット・ヘルスケア・プロダクツ・ベスローテン・フェンノートシャップ 神経疾患を発症する危険性を決定するための方法
GB2414309B (en) 2004-05-18 2009-02-25 Simon Richard Daniel Spherical display and control device
US8431335B2 (en) 2006-09-12 2013-04-30 Genzyme Corporation Compositions and methods for detection of lysosomal storage disease
EP2594564B1 (en) 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
US8026099B2 (en) * 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
EP3078373A1 (en) 2008-10-03 2016-10-12 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitor
US20120052053A1 (en) * 2008-11-14 2012-03-01 Manning-Bog Amy B Compositions and methods for the treatment of altered alpha-synuclein function
US20130178375A1 (en) * 2010-07-23 2013-07-11 President And Fellows Of Harvard College Methods of Detecting Neurological or Neuropsychiatric Diseases or Conditions
RU2018104472A (ru) * 2011-03-18 2019-02-22 Джензим Корпорейшн Ингибиторы глюкозилцерамид-синтазы
JP6061922B2 (ja) * 2011-06-22 2017-01-18 ザ ジェネラル ホスピタル コーポレイション プロテイノパチーの処置方法
US9512463B2 (en) 2011-11-08 2016-12-06 University Of Washington Methods and compositions for assaying the activity of one or more lysosomal enzymes

Also Published As

Publication number Publication date
JP2019513231A (ja) 2019-05-23
KR20180124971A (ko) 2018-11-21
JP2021185377A (ja) 2021-12-09
US20200124624A1 (en) 2020-04-23
MA44484A (fr) 2019-01-30
AU2017238769A1 (en) 2018-11-15
WO2017165766A3 (en) 2017-11-02
JP6940515B2 (ja) 2021-09-29
IL261906A (en) 2018-10-31
JP7250081B2 (ja) 2023-03-31
CA3018745A1 (en) 2017-09-28
EP3433623A2 (en) 2019-01-30
WO2017165766A2 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
WO2017070114A3 (en) Diabetes-related biomarkers and treatment of diabetes-related conditions
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX2018011679A (es) Biomarcadores de proteopatias y usos de los mismos.
MX2025006655A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos
MX2017008904A (es) Biomarcadores basados en sangre para diagnosticar enfermedad de arteria coronaria ateroesclerotica.
EP4293358A3 (en) Volatile organic compounds as cancer biomarkers
BR112014031365A2 (pt) métodos de detectar doenças ou condições
EP4403649A3 (en) Biomarkers of traumatic brain injury
EP4345159A3 (en) Methods for trapping and barcoding discrete biological units in hydrogel
HK1247250A1 (zh) 用於指导癌症治疗的内容相关的诊断测试
MX2017003370A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
WO2015034886A3 (en) Wellness panel for companion animals
BR112019005172A2 (pt) método e kit para analisar uma amostra
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
WO2018022604A3 (en) Methods of diagnosing and treating alzheimer's disease with s-equol
GB2552271A (en) A method for diagnosing lung cancer
EP3640643A3 (en) Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
RU2014113841A (ru) Способ ранней диагностики эндогенной интоксикации
BR112019005179A2 (pt) método e kit para analisar uma amostra
EP4328324A3 (en) Methods of diagnosing epilepsy
WO2015134791A3 (en) Non-invasive biomarker of antibody-mediated allograft rejection
GB0713363D0 (en) Diagnosis and treatment of abnormal blood conditions
UA109431U (uk) Спосіб діагностики розвитку остеопорозу
UA109433U (uk) Спосіб діагностики розвитку остеопорозу
UA109515U (uk) Спосіб діагностики розвитку остеопорозу